Alkeus Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• ALK-001 oral capsule · Ophthalmology
  ALK-001 is a retinoid that reduces toxic bisretinoid accumulation in the retina by inhibiting the visual cycle.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Alkeus Pharmaceuticals, Inc. portfolio CI brief
• Alkeus Pharmaceuticals, Inc. pipeline updates RSS